Mannatech: Share Price Staying Strong
Mannatech is fast becoming a robust identity both within the
health and wellness industry and on the stock market. The
company has made a conscious effort to promote itself as a
cutting edge organization, firmly grounded in scientifically
validated nutritional products. (http://www.mannacentre.com) So
far they seem to be succeeding, although Mannatech's popularity
has been met with considerable skepticism from the
pharmaceutical drug industry.
In fact based on the negative press that Mannatech has received
from some of the more conservative sectors of the medical
industry, it would be easy to conclude that Mannatech is just
another short term boom and bust fad, conjured up by
entrepreneurial gamblers. A deeper look at this company soon
reveals a far different reality that exudes substance and
integrity. In fact Mannatech's rapid but consistent growth both
geographically and in unit sales over the past 12 years, has
been sufficient to convince the NASDAQ that Mannatech is here to
stay. The stock price is hovering at just under $13 which
translates into a resounding vote of confidence, within industry
that has traditionally been plagued by peddlers of "snake oil".
Much of the financial interest has been generated by cumulative
sales of the company, which just exceeded $1.5 billion and
annual sales numbers that have more than doubled in just two
years.
The product that forms the core of Mannatech's business is
Ambrotose, which has been secured with a range of patents that
look certain to keep Mannatech's flagship in tact for many years
to come. However, the major "blip" on the radar for this company
lies in how its sale will react to the slow down of the US
economy. Some are predicting a volatile reaction as consumers
may seek to cut luxury items to compensate for the rising cost
of living. (http://www.mannatechnews.com) Mannatech on the other
hand remain confident that their products are fast becoming a
core health product, capable of withstanding considerable
financial pressure.